Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Publication year range
1.
Med. intensiva (Madr., Ed. impr.) ; 36(7): 513-515, oct. 2012. ilus, tab
Article in Spanish | IBECS | ID: ibc-109922

ABSTRACT

Existen pocos datos sobre los pacientes con estenosis aórtica grave (EAG) que requieren ingreso en unidades de cuidados intensivos cardiológicos (UCIC). Se estudió a 27 pacientes con EAG ingresados en la UCIC de un hospital terciario. Los motivos de ingreso más frecuentes fueron insuficiencia cardiaca grave (42%), síndrome coronario agudo (39%) y parada cardiorrespiratoria (8%). Tras un seguimiento medio de 6,5 meses, 11 pacientes fallecieron y la supervivencia fue del 74±8, el 70±9 y el 62±10% a los 7, 30 y 60 días, respectivamente. De los 27 pacientes, a 13 (48%) se los intervino quirúrgicamente, estos pacientes presentaron un menor índice EuroSCORE (el 13±11 versus el 34±18%; p=0,002) y una mayor supervivencia (el 92±7% a los 7, 30 y 60 días versus el 50±13, el 40±14 y el 30±14%; p=0,002). Por tanto, los pacientes con EAG que requieren ingreso en las UCIC presentan muy alto riesgo, con una elevada mortalidad que se concentra especialmente en la primera semana de hospitalizacion y en los pacientes no intervenidos quirúrgicamente (AU)


There is little information about patients with severe aortic stenosis (SAS) who require admission to acute care units. We studied 27 patients with SAS admitted in a tertiary hospital coronary care unit. The most frequent reasons for admission were severe heart failure (42%), acute coronary syndrome (39%) and cardiac arrest (8%). At a mean follow-up of 6.5 months, 11 patients died. Cumulative survival was 74±8%, 70±9%, and 62±10% at 7, 30 and 60 days, respectively. Out of the 27 patients, 13 (48%) underwent surgical intervention, these patients having lower Euroscore (13±11 vs. 34±18%, p=0.002) and higher survival (92±7% at 7, 30 and 60 days vs. 50±13%, 40±14% and 30±14%; p=0.002). Thus, patients with SAS who require hospitalization in the intensive care units constitute a very high risk population, with very high mortality, especially during the first week after admission and in patients who have not undergone surgery (AU)


Subject(s)
Humans , Aortic Valve Stenosis/complications , Heart Failure/epidemiology , Acute Coronary Syndrome/epidemiology , Heart Arrest/epidemiology , Critical Illness , Intensive Care Units/statistics & numerical data , Risk Factors
2.
Med Intensiva ; 36(7): 513-5, 2012 Oct.
Article in Spanish | MEDLINE | ID: mdl-20219267

ABSTRACT

There is little information about patients with severe aortic stenosis (SAS) who require admission to acute care units. We studied 27 patients with SAS admitted in a tertiary hospital coronary care unit. The most frequent reasons for admission were severe heart failure (42%), acute coronary syndrome (39%) and cardiac arrest (8%). At a mean follow-up of 6.5 months, 11 patients died. Cumulative survival was 74±8%, 70±9%, and 62±10% at 7, 30 and 60 days, respectively. Out of the 27 patients, 13 (48%) underwent surgical intervention, these patients having lower Euroscore (13±11 vs. 34±18%, p=0.002) and higher survival (92±7% at 7, 30 and 60 days vs. 50±13%, 40±14% and 30±14%; p=0.002). Thus, patients with SAS who require hospitalization in the intensive care units constitute a very high risk population, with very high mortality, especially during the first week after admission and in patients who have not undergone surgery.


Subject(s)
Aortic Valve Stenosis , Aged , Aged, 80 and over , Aortic Valve Stenosis/mortality , Aortic Valve Stenosis/therapy , Critical Illness , Female , Humans , Male , Middle Aged , Prognosis , Severity of Illness Index , Survival Rate
3.
Int J Cardiol ; 148(3): e60-2, 2011 May 05.
Article in English | MEDLINE | ID: mdl-19356812

ABSTRACT

We report a 20 year old patient with repaired Tetralogy of Fallot who presented with acute right side heart failure. The echocardiogram showed severe mitral regurgitation which was not present one year before. Because of mitral insufficiency, pulmonary pressure increased and it was nearby 70% systemic pressure. Pulmonary regurgitation got worse, and the patient came to the hospital in a state of anasarca. After valve replacement, histopathological study of the mitral valve and the aortic valve revealed Aschoff nodules and rheumatic fever was confirmed.


Subject(s)
Heart Failure/diagnosis , Rheumatic Fever/diagnosis , Tetralogy of Fallot/surgery , Age Factors , Diagnosis, Differential , Heart Defects, Congenital/complications , Heart Defects, Congenital/surgery , Heart Failure/etiology , Humans , Male , Rheumatic Fever/etiology , Tetralogy of Fallot/complications , Young Adult
4.
Cardiovasc Hematol Agents Med Chem ; 7(3): 212-22, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19689260

ABSTRACT

Endothelial dysfunction is characterized by an impairment of endothelium-dependent vasodilatation. It has been linked to each of the known atherogenic risk factors, including diabetes mellitus, hypertension, dyslipidaemia, cigarette smoking, menopause, etc. A number of recent studies have shown that the severity of endothelial dysfunction correlates with the development of coronary artery disease and predicts future cardiovascular events. Therefore, these findings strengthen the hypothesis that endothelial dysfunction may be an early stage of coronary atherosclerosis. This phenomenon primarily reflects an imbalance between the vasodilating (nitric oxide) and vasoconstrictor agents (endothelin-1). Several invasive (intracoronary or intrabrachial infusions of vasoacting agents) and non-invasive techniques (assessment of flow mediated vasodilatation in the brachial artery by ultrasound) have been developed during the last few years to evaluate endothelial function in the coronary and peripheral circulation. This new methodology has allowed assessing the severity of the abnormalities in vascular function and their regression by several pharmacological and non-pharmacological interventions. It is likely that restoration of endothelial function can regress the atherosclerotic disease process and prevent future cardiovascular events. Most pharmacological interventions attempting to improve endothelial dysfunction targeted the risk factors linked to endothelial dysfunction: hypertension (ACE-inhibitors, calcium antagonists), dyslipidaemia (lipid-lowering agents) and menopause (estrogens). Nevertheless, several pharmacological agents have been suggested to achieve vascular protection through different mechanisms beyond their primary therapeutic actions: ACE-inhibitors, statins, third generation of beta-blockers (nebivolol), endothelium-derived nitric oxide synthesis (tetrahydrobiopterin, BH4) and antioxidants agents. In this review we will focus on the current pharmacological management of the endothelial dysfunction.


Subject(s)
Endothelium/drug effects , Endothelium/physiopathology , Adrenergic beta-Antagonists/pharmacology , Adrenergic beta-Antagonists/therapeutic use , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Atherosclerosis/etiology , Calcium Channel Blockers/pharmacology , Calcium Channel Blockers/therapeutic use , Folic Acid/pharmacology , Folic Acid/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Nitrates/pharmacology , Nitrates/therapeutic use , Nitric Oxide/pharmacology , Nitric Oxide/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...